Brandee Lynn Wagner

US Patent:

20030086928, May 8, 2003

Filed:

Sep 17, 2002

Appl. No.:

10/247279

Inventors:

Marc Montminy - San Diego CA, US
Brandee Wagner - San Diego CA, US

International Classification:

A61K039/395
C07K016/40

US Classification:

424/146100, 530/388260

Abstract:

The present invention relates to compositions which specifically bind to a multimeric protein complex but not to the individual and separate components of the complex, or alternatively, compositions which specifically bind to individual and separate components but not to any complex thereof. The present invention also relates to methods of using such compositions for identifying compounds that promote multimeric complex formation and/or disruption and for treating disorders associated with aberrant complex formation by modulating the formation and/or disruption of multimeric protein complexes.

US Patent:

20030228607, Dec 11, 2003

Filed:

Apr 14, 2003

Appl. No.:

10/414692

Inventors:

Brandee Wagner - San Diego CA, US
Ira Schulman - San Diego CA, US

International Classification:

C12Q001/68
G01N033/53
G01N033/567
C07K014/705

US Classification:

435/006000, 435/007200, 530/358000

Abstract:

This invention relates to methods for identifying agents useful for treatment of diseases and pathological conditions affected by nuclear receptors and there associated co-factors, and agents and compositions having an improved therapeutic profile identified using such screening methods.

US Patent:

20090098570, Apr 16, 2009

Filed:

Jun 26, 2006

Appl. No.:

11/921967

Inventors:

Naoki Terasaka - Saitama-shi, JP
Shoko Honzumi - Tokyo, JP
Ira Glenn Schulman - San Diego CA, US
Brandee Lynn Wagner - San Diego CA, US
Patricia J. Willy - San Diego CA, US

International Classification:

G01N 33/53
C07K 14/435
C12N 15/12
C12N 15/85
C12N 5/10

US Classification:

435 71, 436501, 530350, 530324, 530325, 530326, 536 231, 4353201, 435325

Abstract:

A method of easily measuring whether or not an LXR ligand has the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration in a mammal by using the binding activity between LXR and a coactivator, and a method of identifying LXR ligands that do not have the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration by using the binding activity between LXR and a coactivator.

US Patent:

20220323414, Oct 13, 2022

Filed:

Jun 9, 2022

Appl. No.:

17/836905

Inventors:

- San Diego CA, US
Hubert CHEN - San Diego CA, US
Brandee WAGNER - San Diego CA, US

International Classification:

A61K 31/415
A61P 1/16
A61K 9/00
A61K 45/06

Abstract:

Described herein are combination therapies with farnesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

US Patent:

20230131804, Apr 27, 2023

Filed:

Mar 17, 2021

Appl. No.:

17/906580

Inventors:

- San Diego CA, US
Hubert CHEN - San Diego CA, US
Brandee WAGNER - San Diego CA, US
Nicholas D. SMITH - San Diego CA, US

International Classification:

A61K 31/4439
A61K 45/06
A61P 1/16
A61P 1/04
A61P 35/00

Abstract:

Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.

US Patent:

20190153444, May 23, 2019

Filed:

Sep 25, 2018

Appl. No.:

16/140881

Inventors:

- San Diego CA, US
Neil W. Gibson - San Diego CA, US
Diedre MacKenna - San Diego CA, US
Brandee Wagner - La Jolla CA, US
David P. Bartel - Brookline MA, US

Assignee:

Regulus Therapeutics Inc. - San Diego CA

International Classification:

C12N 15/113
A61K 31/713
A61K 47/54
A61K 31/7088
A61K 45/06

Abstract:

Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.

US Patent:

20180171334, Jun 21, 2018

Filed:

Oct 5, 2017

Appl. No.:

15/725843

Inventors:

- San Diego CA, US
Neil W. Gibson - San Diego CA, US
Diedre MacKenna - San Diego CA, US
Brandee Wagner - La Jolla CA, US
David P. Bartel - Brookline MA, US

Assignee:

Regulus Therapeutics Inc. - San Diego CA

International Classification:

C12N 15/113
A61K 31/7088
A61K 31/713
A61K 45/06
A61K 47/54

Abstract:

Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.

US Patent:

20170067051, Mar 9, 2017

Filed:

Sep 22, 2016

Appl. No.:

15/272619

Inventors:

- San Diego CA, US
Neil W. Gibson - San Diego CA, US
Diedre MacKenna - San Diego CA, US
Brandee Wagner - La Jolla CA, US
David P. Bartel - Brookline MA, US

Assignee:

Regulus Therapeutics Inc. - San Diego CA

International Classification:

C12N 15/113
A61K 31/713
A61K 47/48

Abstract:

Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.